Moreover, Chondroitin Sulfate Proteoglycan 4 (CSPG4) exhibits increased expression in various cancers, including melanoma, breast cancer, and renal cell carcinoma, positioning it as a potential target for antitumor immunotherapy [36]. The gene discussed is CSPG4; the disease is melanoma.